North America Immuno Oncology Assays Market Size, Share & Segmentation Report 2025-2035
The North America Immuno Oncology Assays Market is witnessing robust growth driven by advances in cancer immunotherapy, technological innovations in molecular diagnostics, and rising demand for personalized medicine. The sector encompasses reagents, kits, instruments, software, and a wide spectrum of applications such as clinical diagnostics, biomarker discovery, and companion diagnostics. Key players are investing in enhancing assay accuracy, automation, and multiomics integration, shaping the competitive landscape. With the increasing prevalence of cancer and uptake of novel therapies, North America is positioned as a global leader, with the US leading in market share and innovation.
Latest Market Dynamics
Key Drivers
Growth in immunotherapy adoption: The increasing clinical acceptance of cancer immunotherapies is driving demand for immuno oncology assays, with companies like Roche and Thermo Fisher innovating advanced biomarker panels.
Expansion of precision medicine: Personalized treatment protocols have accelerated the need for companion diagnostics, with Illumina and Agilent launching NGS and multiplex platforms for tailored cancer management.
Key Trends
Shift to multiomics platforms: Companies such as QIAGEN and BD are integrating multiomics data to provide comprehensive immune profiling, enhancing assay capability and clinical relevance.
Adoption of digital & AI-driven diagnostics: Vendors like Abbott and Siemens Healthineers are embedding AI tools in assay workflows, allowing real-time interpretation and decision-making support.
Key Opportunities
Expansion in biomarker companion diagnostics: Roche’s latest FDA approvals for companion diagnostics open new opportunities for drug-assay co-development, improving treatment outcomes.
Growth in decentralized and point-of-care testing: Players including Bio-Rad and PerkinElmer are focusing on portable assay solutions for community oncology centers, increasing accessibility and turnaround.
Key Challenges
Regulatory complexity: Companies such as Danaher face challenges keeping pace with evolving North American regulatory standards for multiplex and genomic assays.
Integration and interoperability hurdles: The integration of new assay technologies into existing hospital information systems remains a challenge, as seen with Thermo Fisher’s and BD’s ongoing system adaptations.
Key Restraints
High costs of advanced technologies: Market adoption is restrained by the significant costs of NGS and digital platforms, limiting accessibility for mid-sized labs, affecting companies like Illumina and Agilent.
Limited skilled workforce: A shortage of trained molecular oncology professionals impedes optimal assay adoption, highlighted by ongoing training initiatives from Abbott and Siemens Healthineers.
In 2025, Reagents & Kits hold the dominant position in the North America Immuno Oncology Assays Market, reflecting their frequent use in both research and clinical diagnostics. Instruments and Software & Services follow as essential components supporting high-throughput and data-driven analysis. The growing emphasis on automation, standardization, and integration of digital health solutions is pushing demand particularly for software-enabled assay platforms.
Clinical Diagnostics represent the largest share in application, driven by their integration in cancer detection, patient monitoring, and therapeutic selection. Research applications are robust, fueled by active oncology research initiatives, while Drug Development leverages advanced assays for clinical trials and preclinical validation. The increasing focus on personalized medicine and the use of biomarker discovery tools is expected to accelerate application diversification.
The North America Immuno Oncology Assays Market is projected to exhibit steady revenue growth from 2020 to 2035, with total market size expected to reach approximately 4,200 Million USD by 2035, up from 1,850 Million USD in 2025. Expansion is supported by the growing adoption of precision oncology solutions and increasing research investments. The rise of decentralized diagnostic platforms and enhanced reimbursement frameworks are likely to accelerate future revenue streams.
Year-over-year growth for the North America Immuno Oncology Assays Market demonstrates a strong upward trajectory, peaking around 2027-2029 as novel therapies and diagnostics reach market maturity. Although growth moderates post-2031, sustained advancements in assay technology, favorable reimbursement, and deeper clinical integration sustain a robust market outlook.
The United States holds the largest regional share in 2025, reflective of its advanced healthcare infrastructure, high research funding, and rapid adoption of novel oncology assays. Canada follows, benefiting from national cancer programs and clinical trial activity, while Mexico is experiencing steady growth, primarily in private healthcare and academic research collaborations.
Market leadership in 2025 is demonstrated by Thermo Fisher Scientific and F. Hoffmann-La Roche AG, owing to their comprehensive assay portfolios and innovation pipelines. Illumina also commands significant share, especially in NGS technology, reflecting sustained R&D focus and commercial partnerships. The competitive landscape is diversified but dominated by these top players.
Hospital Pharmacies continue to be the leading buyers in 2025 due to the critical role of immuno oncology assays in routine diagnostics and patient management. Academic & Research Institutes form the second largest segment, leveraging assays for translational research and clinical trials. Increasing participation of Contract Research Organizations (CROs) highlights the trend towards outsourced research and rapid assay development.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
1850
Regions
US, Canada, Mexico
Segments
By Type, By Application, By Distribution Channels, By Technology, By Organization Size
June 2024: Thermo Fisher Scientific launched a new multiplex immuno oncology assay for early cancer detection utilizing next-generation sequencing and digital pathology integration.
July 2024: Illumina expanded its companion diagnostics offering with a new FDA-approved assay panel for solid tumor immunotherapy selection.
August 2024: Roche announced a strategic partnership with a major US cancer center to develop AI-driven immuno oncology testing for personalized treatments.
September 2024: Siemens Healthineers introduced cloud-based oncology assay management software to enhance workflow automation in major health systems.
October 2024: Agilent Technologies unveiled a portable immuno oncology testing platform targeting decentralized and point-of-care cancer diagnostics.
Frequently Asked Questions
About the Author
Clara
Senior Market Research Analyst
Clara is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Clara brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Clara has helped organizations translate data into actionable growth strategies.
